Collegium Pharmaceutical (COLL) shares rose by nearly 13% in recent trading on Wednesday after the company provided 2025 guidance.
Collegium said it expects 2025 product revenue of between $735 million to $750 million. Analysts polled by FactSet expect $739.9 million.
Jornay PM, an attention-deficit/hyperactivity disorder drug, is positioned to be the lead growth driver, with expected net revenue of more than $135 million in 2025, Collegium said.
Price: 32.82, Change: +3.68, Percent Change: +12.63
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.